{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:59:26Z","timestamp":1790758766851,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001126","name":"Geisinger Health System Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012127","name":"Augusta University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012127","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.bcp.2019.08.015","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T20:26:16Z","timestamp":1566419176000},"page":"113613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["M3 muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKK\u03b2\/AMPK pathway"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-454X","authenticated-orcid":false,"given":"Ravirajsinh N.","family":"Jadeja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0023-0047","authenticated-orcid":false,"given":"Sandeep","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2019.08.015_b0005","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U. S.","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2019.08.015_b0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bcp.2019.08.015_b0015","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jhep.2005.06.008","article-title":"Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease","volume":"43","author":"Suzuki","year":"2005","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.bcp.2019.08.015_b0020","first-page":"1396","article-title":"Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"6","author":"Mummadi","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"5","key":"10.1016\/j.bcp.2019.08.015_b0025","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.bcp.2019.08.015_b0030","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.bcp.2019.08.015_b0035","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"18","key":"10.1016\/j.bcp.2019.08.015_b0040","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"New Engl. J. Med."},{"issue":"16","key":"10.1016\/j.bcp.2019.08.015_b0045","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bcp.2019.08.015_b0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-142-1-200501040-00110","article-title":"Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality","volume":"142","author":"Miller","year":"2005","journal-title":"Ann. Intern. Med."},{"issue":"14","key":"10.1016\/j.bcp.2019.08.015_b0055","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.bcp.2019.08.015_b0060","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2019.08.015_b0065","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2019.08.015_b0070","doi-asserted-by":"crossref","first-page":"C221","DOI":"10.1152\/ajpcell.00514.2008","article-title":"Muscarinic receptors and ligands in cancer","volume":"296","author":"Shah","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bcp.2019.08.015_b0075","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.freeradbiomed.2014.09.032","article-title":"M1 muscarinic receptors modify oxidative stress response to acetaminophen-induced acute liver injury","volume":"78","author":"Urrunaga","year":"2015","journal-title":"Free Radical Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2019.08.015_b0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.bcp.2013.05.010","article-title":"Effects of modulating M3 muscarinic receptor activity on azoxymethane-induced liver injury in mice","volume":"86","author":"Khurana","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2019.08.015_b0085","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1124\/jpet.109.165118","article-title":"Scopolamine treatment and muscarinic receptor subtype-3 gene ablation augment azoxymethane-induced murine liver injury","volume":"333","author":"Khurana","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2019.08.015_b0090","doi-asserted-by":"crossref","first-page":"14110","DOI":"10.1038\/srep14110","article-title":"M1 muscarinic receptor deficiency attenuates azoxymethane-induced chronic liver injury in mice","volume":"5","author":"Rachakonda","year":"2015","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2019.08.015_b0095","doi-asserted-by":"crossref","first-page":"e44813","DOI":"10.1371\/journal.pone.0044813","article-title":"Vagus nerve stimulation reduces body weight and fat mass in rats","volume":"7","author":"Banni","year":"2012","journal-title":"PLoS ONE"},{"issue":"7\u20138","key":"10.1016\/j.bcp.2019.08.015_b0100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2119\/molmed.2011.00083","article-title":"Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice","volume":"17","author":"Satapathy","year":"2011","journal-title":"Mol. Med."},{"issue":"2\u20134","key":"10.1016\/j.bcp.2019.08.015_b0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000351719","article-title":"Next-generation sequence analysis of genes associated with obesity and nonalcoholic fatty liver disease-related cirrhosis in extreme obesity","volume":"75","author":"Gerhard","year":"2013","journal-title":"Hum. Hered."},{"issue":"3","key":"10.1016\/j.bcp.2019.08.015_b0110","first-page":"304","article-title":"High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis","volume":"166","author":"Leti","year":"2015","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"issue":"1","key":"10.1016\/j.bcp.2019.08.015_b0115","first-page":"95","article-title":"Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells","volume":"2","author":"Cui","year":"2010","journal-title":"Am J Transl Res"},{"issue":"4","key":"10.1016\/j.bcp.2019.08.015_b0120","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/ajcn\/76.4.750","article-title":"Adipose tissue biomarkers of fatty acid intake","volume":"76","author":"Baylin","year":"2002","journal-title":"Am. J. Clin. Nutr."},{"issue":"12","key":"10.1016\/j.bcp.2019.08.015_b0125","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1194\/jlr.R025882","article-title":"AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases","volume":"53","author":"Srivastava","year":"2012","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.bcp.2019.08.015_b0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1748-1716.2009.01970.x","article-title":"AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives","volume":"196","author":"Viollet","year":"2009","journal-title":"Acta Physiol. (Oxf.)"},{"issue":"Suppl. 4","key":"10.1016\/j.bcp.2019.08.015_b0135","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1038\/ijo.2008.124","article-title":"The regulation of AMP-activated protein kinase by upstream kinases","volume":"32","author":"Carling","year":"2008","journal-title":"Int. J. Obes. (Lond.)"},{"key":"10.1016\/j.bcp.2019.08.015_b0140","doi-asserted-by":"crossref","unstructured":"T.-A. Kudo, H. Kanetaka, K. Mizuno, Y. Ryu, Y. Zhang, M. Kano, Y. Shimizu, H. Hayashi, Effects of the Small Molecule Dorsomorphin on Intracellular Signaling, 2012, pp. 131\u2013133.","DOI":"10.1007\/978-4-431-54070-0_31"},{"issue":"1","key":"10.1016\/j.bcp.2019.08.015_b0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.116.236125","article-title":"The M1 muscarinic receptor antagonist VU0255035 delays the development of status epilepticus after organophosphate exposure and prevents hyperexcitability in the basolateral amygdala","volume":"360","author":"Miller","year":"2017","journal-title":"J. Pharmacol. Experim. Therap."},{"issue":"3","key":"10.1016\/j.bcp.2019.08.015_b0150","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF01005057","article-title":"Cholinergic nerves in the human liver","volume":"13","author":"Amenta","year":"1981","journal-title":"Histochem. J."},{"issue":"2","key":"10.1016\/j.bcp.2019.08.015_b0155","first-page":"81","article-title":"Ultrastructure of cholinergic innervation in the cirrhotic liver in guinea pigs. Neurohistochemical and ultrastructural study, Virchows Archiv. B","volume":"57","author":"Akiyoshi","year":"1989","journal-title":"Cell Pathol. Include. Mol. Pathol."},{"issue":"5","key":"10.1016\/j.bcp.2019.08.015_b0160","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1600-0676.1998.tb00817.x","article-title":"A comparative histochemical and immunohistochemical study of aminergic, cholinergic and peptidergic innervation in rat, hamster, guinea pig, dog and human livers","volume":"18","author":"Akiyoshi","year":"1998","journal-title":"Liver"},{"issue":"2","key":"10.1016\/j.bcp.2019.08.015_b0165","first-page":"275","article-title":"The vagal contribution to the rat liver innervation: a demonstration with the cobalt impregnation method, Comparative biochemistry and physiology. A","volume":"86","author":"Azanza","year":"1987","journal-title":"Comparat. Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2019.08.015_b0170","first-page":"275","article-title":"The autonomic innervation of the liver and gallbladder of Podarcis hispanica","volume":"5","author":"Azanza","year":"1990","journal-title":"Histol. Histopathol."},{"issue":"4","key":"10.1016\/j.bcp.2019.08.015_b0175","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1124\/pr.110.003350","article-title":"The significance of G protein-coupled receptor crystallography for drug discovery","volume":"63","author":"Salon","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2019.08.015_b0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrd3320","article-title":"G protein-coupled receptors: novel targets for drug discovery in cancer","volume":"10","author":"Lappano","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bcp.2019.08.015_b0185","first-page":"115","article-title":"Targeting G protein coupled receptor-related pathways as emerging molecular therapies","volume":"23","author":"Ghanemi","year":"2015","journal-title":"Saudi Pharm. J. SPJ Off. Publ. Saudi Pharm. Soc."},{"issue":"7","key":"10.1016\/j.bcp.2019.08.015_b0190","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd4295","article-title":"Muscarinic acetylcholine receptors: novel opportunities for drug development","volume":"13","author":"Kruse","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.08.015_b0195","doi-asserted-by":"crossref","unstructured":"A.R. Bolbecker, A. Shekhar, Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions, Handbook of Experimental Pharmacology, vol. 208, 2012, pp. 167\u201390.","DOI":"10.1007\/978-3-642-23274-9_8"},{"issue":"2","key":"10.1016\/j.bcp.2019.08.015_b0200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1574889809666141120131238","article-title":"Pharmacological approaches to targeting muscarinic acetylcholine receptors","volume":"9","author":"Matera","year":"2014","journal-title":"Recent Pat. CNS Drug Discov."},{"issue":"1","key":"10.1016\/j.bcp.2019.08.015_b0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/14728222.12.1.91","article-title":"AMP activated protein kinase: a next generation target for total metabolic control","volume":"12","author":"Misra","year":"2008","journal-title":"Exp. Opin. Therap. Targ."},{"issue":"7","key":"10.1016\/j.bcp.2019.08.015_b0210","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1172\/JCI67227","article-title":"AMPK, insulin resistance, and the metabolic syndrome","volume":"123","author":"Ruderman","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.bcp.2019.08.015_b0215","doi-asserted-by":"crossref","first-page":"891S","DOI":"10.3945\/ajcn.110.001925","article-title":"Sensing of energy and nutrients by AMP-activated protein kinase","volume":"93","author":"Hardie","year":"2011","journal-title":"Am. J. Clin. Nutr."},{"issue":"25","key":"10.1016\/j.bcp.2019.08.015_b0220","doi-asserted-by":"crossref","first-page":"17116","DOI":"10.1074\/jbc.M708987200","article-title":"Muscarinic receptor activation of AMP-activated protein kinase inhibits orexigenic neuropeptide mRNA expression","volume":"283","author":"Thornton","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2019.08.015_b0225","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cellsig.2010.03.004","article-title":"The M3-muscarinic acetylcholine receptor stimulates glucose uptake in L6 skeletal muscle cells by a CaMKK-AMPK-dependent mechanism","volume":"22","author":"Merlin","year":"2010","journal-title":"Cell. Sign."},{"issue":"3","key":"10.1016\/j.bcp.2019.08.015_b0230","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.bcp.2019.08.015_b0235","first-page":"809","article-title":"Roles of PPARs in NAFLD: potential therapeutic targets","volume":"1821","author":"Tailleux","year":"2012","journal-title":"BBA"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629521930303X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629521930303X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:06:17Z","timestamp":1757768777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629521930303X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":47,"alternative-id":["S000629521930303X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.08.015","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M3 muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKK\u03b2\/AMPK pathway","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113613"}}